BioGen Technologies

Biogen is a publicly traded global biotechnology company focused primarily on neuroscience, immunology, and rare diseases. The company markets multiple approved therapies across multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, amyotrophic lateral sclerosis, and postpartum depression, and it also participates in Alzheimer’s disease commercialization through its collaboration with Eisai. Biogen combines internal R&D with business development and partnership-driven pipeline expansion, with current pipeline activity spanning neurology, immunology, and rare disease. The company also maintains substantial large-scale biologics and advanced manufacturing capabilities in the United States, especially in North Carolina, and is one of the oldest independent biotech companies.